Le Lézard
Classified in: Health, Science and technology

73% of Respondents Say One or More Diseases Run in Their Family; Just 6% Don't Want Genetic Testing -- Wamberg Genomic Survey



LA JOLLA, Calif., Dec. 7, 2017 /PRNewswire/ -- Seventy-three percent of respondents noted that common diseases run in their family.  The top diseases cited were diabetes 37%, cancer 35%, heart disease 32%, and depression/mental health issues 31%.  Just 6% would decline free genetic testing to better predict future occurrence of diseases. Fifty-three percent (53%) of respondents noted that they would definitely accept free genetic testing to better predict future occurrence of diseases, another 29% may want it, and 12% were unsure.

Wamberg Genomic Advisors' mission is to make genomic testing readily available at prices everyone can afford. The firm's focus is on delivering genomic products and services to employers and their employees via their trusted benefit brokers, and policyholders of life insurance companies (PRNewsfoto/Wamberg Genomic Advisors)

Results are based on Wamberg Genomic Consumer Survey, which queried 536 U.S. consumers from 26 to 64 years old with employer-sponsored health insurance. Survey Sampling International (SSI) fielded the survey in October/November 2017.

According to Dr. Phil Smalley, Chief Medical Director of Wamberg Genomic Advisors, "These results indicate that the public seems to understand that knowing their genetics can help lower their risk of developing diseases that run in their family."

Results from the survey questions are below:

Do any of these diseases run in your family? *

If you were offered free genetic testing to better predict future occurrence of diseases and the results were private and confidential, would you want to get your own genetics tested?

For the first time, individuals and their families can access the following tests and reports to help their care providers better manage health:

Other results of the survey revealed the following:

About the Survey
The Wamberg Genomic Consumer Survey queried 536 U.S. consumers 26-64. The survey was fielded by Survey Sampling International (SSI) in October/November 2017. Data for the survey was collected via an opt-in panel. The margin of error was 4%.

About Survey Sampling International:

Survey Sampling International (SSI) has been the premier global provider of data solutions and technology for consumer and business-to-business survey research for 40 years.  For more information, go to www.surveysampling.com.   

About Wamberg Genomic Advisors:

Wamberg Genomic Advisors' mission is to make genomic testing readily available at prices everyone can afford. Our focus is on delivering genomic products and services to employers and their employees via their trusted benefit brokers, and policyholders of life insurance companies. To learn more, visit wamberggenomic.com.

*Note percentages can add to more than 100% as respondents can choose multiple answers

SOURCE Wamberg Genomic Advisors


These press releases may also interest you

at 11:01
Athletico Physical Therapy has opened a new location in Dearborn Heights on Monday, February 19th at 26945 Ford Road, Dearborn Heights, MI 48127. Athletico is looking forward to continuing its quality of care throughout the Metro Detroit area....

at 11:00
The "Global Chromatography Market - Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering. The Global Chromatography Market is Expected to Reach $18 Billion by 2024 Chromatography is the one of the various separation...

at 11:00
Seventh Sense Biosystems (7SBio) today announced a paper published in Nature Biomedical Engineering that compares the performance of the company's TAP® device to traditional venipuncture. TAP is a virtually painless, one-step blood collection device...

at 11:00
Anew Era TMS, serving Orange County, California, is a provider of transcranial magnetic stimulation (TMS) for treating individuals with medication-resistant depression and co-occurring disorders. TMS offers a safe and noninvasive treatment option...

at 10:44
Minor orthopedic replacement implants manufacturing companies develop, market and distribute orthopedic implant products for commercial use. Products are usually sold to hospitals, for use during orthopedic replacement surgery. The right type of...

at 10:17
Though not likely to immediately realize the billion-dollar revenues projected in many sources, molecular point-of-care is here to say, says market researcher Kalorama Information.  The molecular point-of-care market, consisting of systems with...




News published on 7 december 2017 at 18:02 and distributed by: